Satyan M. Rajbhandari

Prof. Dr. Satyan M. Rajbhandari

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2018 in IEEE Transactions on Emerging Topics in Computational Intelligence
Verified
Journal Article
Closed access
MGManu Goyal
Manu Goyal
NRNeil D Reeves
Neil D Reeves
ADAdrian K. Davison
Adrian K. Davison
SRSatyan M. Rajbhandari
Satyan M. Rajbhandari
JSJennifer Spragg
Jennifer Spragg
MYMoi Hoon Yap
Moi Hoon Yap
Globally, in 2016, 1 out of 11 adults suffered from diabetes mellitus. Diabetic foot ulcers (DFU) are a major complication of this disease, which if not managed properly can lead to amputation. Current clinical approaches to DFU treatment rely on patient and clinician vigilance, which has significant limitations, such as the high cost involved in the diagnosis, treatment, and lengthy care of the DFU. We collected an extensive dataset of foot images, which contain DFU from different patients. In this DFU classification problem, we assessed the two classes as normal skin (healthy skin) and abnormal skin (DFU). In this paper, we have proposed the use of machine learning algorithms to extract the features for DFU and healthy skin patches to understand the differences in the computer vision perspective. This experiment is performed to evaluate the skin conditions of both classes that are at high risk of misclassification by computer vision algorithms. Furthermore, we used convolutional neural networks for the first time in this binary classification. We have proposed a novel convolutional neural network architecture, DFUNet, with better feature extraction to identify the feature differences between healthy skin and the DFU. Using 10-fold cross validation, DFUNet achieved an AUC score of 0.961. This outperformed both the traditional machine learning and deep learning classifiers we have tested. Here, we present the development of a novel and highly sensitive DFUNet for objectively detecting the presence of DFUs. This novel approach has the potential to deliver a paradigm shift in diabetic foot care among diabetic patients, which represent a cost-effective, remote, and convenient healthcare solution.

6 September 2018 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Open access
MGManu Goyal
Manu Goyal
NRNeil D Reeves
Neil D Reeves
SRSatyan M. Rajbhandari
Satyan M. Rajbhandari
MYMoi Hoon Yap
Moi Hoon Yap
Current practice for Diabetic Foot Ulcers (DFU) screening involves detection and localization by podiatrists. Existing automated solutions either focus on segmentation or classification. In this work, we design deep learning methods for real-time DFU localization. To produce a robust deep learning model, we collected an extensive database of 1775 images of DFU. Two medical experts produced the ground truths of this dataset by outlining the region of interest of DFU with an annotator software. Using 5-fold cross-validation, overall, Faster R-CNN with InceptionV2 model using two-tier transfer learning achieved a mean average precision of 91.8%, the speed of 48 ms for inferencing a single image and with a model size of 57.2 MB. To demonstrate the robustness and practicality of our solution to real-time prediction, we evaluated the performance of the models on a NVIDIA Jetson TX2 and a smartphone app. This work demonstrates the capability of deep learning in real-time localization of DFU, which can be further improved with a more extensive dataset.

1 October 2022 in Health Technology Assessment
Verified
Journal Article
Closed access
PDF file
STSolomon Sime Tesfaye
Solomon Sime Tesfaye
GSGordon Sloan
Gordon Sloan
JPJennifer Petrie
Jennifer Petrie
DWDavid White
David White
MBMike Bradburn
Mike Bradburn
DSDinesh Selvarajah
Dinesh Selvarajah
Background: The mainstay of treatment for diabetic peripheral neuropathic pain is pharmacotherapy, but the current National Institute for Health and Care Excellence guideline is not based on robust evidence, as the treatments and their combinations have not been directly compared. Objectives: To determine the most clinically beneficial, cost-effective and tolerated treatment pathway for diabetic peripheral neuropathic pain. Design: A randomised crossover trial with health economic analysis. Setting: Twenty-one secondary care centres in the UK. Participants: Adults with diabetic peripheral neuropathic pain with a 7-day average self-rated pain score of ≥ 4 points (Numeric Rating Scale 0–10). Interventions: Participants were randomised to three commonly used treatment pathways: (1) amitriptyline supplemented with pregabalin, (2) duloxetine supplemented with pregabalin and (3) pregabalin supplemented with amitriptyline. Participants and research teams were blinded to treatment allocation, using over-encapsulated capsules and matching placebos. Site pharmacists were unblinded. Outcomes: The primary outcome was the difference in 7-day average 24-hour Numeric Rating Scale score between pathways, measured during the final week of each pathway. Secondary end points included 7-day average daily Numeric Rating Scale pain score at week 6 between monotherapies, quality of life (Short Form questionnaire-36 items), Hospital Anxiety and Depression Scale score, the proportion of patients achieving 30% and 50% pain reduction, Brief Pain Inventory – Modified Short Form items scores, Insomnia Severity Index score, Neuropathic Pain Symptom Inventory score, tolerability (scale 0–10), Patient Global Impression of Change score at week 16 and patients’ preferred treatment pathway at week 50. Adverse events and serious adverse events were recorded. A within-trial cost–utility analysis was carried out to compare treatment pathways using incremental costs per quality-adjusted life-years from an NHS and social care perspective. Results: A total of 140 participants were randomised from 13 UK centres, 130 of whom were included in the analyses. Pain score at week 16 was similar between the arms, with a mean difference of –0.1 points (98.3% confidence interval –0.5 to 0.3 points) for duloxetine supplemented with pregabalin compared with amitriptyline supplemented with pregabalin, a mean difference of –0.1 points (98.3% confidence interval –0.5 to 0.3 points) for pregabalin supplemented with amitriptyline compared with amitriptyline supplemented with pregabalin and a mean difference of 0.0 points (98.3% confidence interval –0.4 to 0.4 points) for pregabalin supplemented with amitriptyline compared with duloxetine supplemented with pregabalin. Results for tolerability, discontinuation and quality of life were similar. The adverse events were predictable for each drug. Combination therapy (weeks 6–16) was associated with a further reduction in Numeric Rating Scale pain score (mean 1.0 points, 98.3% confidence interval 0.6 to 1.3 points) compared with those who remained on monotherapy (mean 0.2 points, 98.3% confidence interval –0.1 to 0.5 points). The pregabalin supplemented with amitriptyline pathway had the fewest monotherapy discontinuations due to treatment-emergent adverse events and was most commonly preferred (most commonly preferred by participants: amitriptyline supplemented with pregabalin, 24%; duloxetine supplemented with pregabalin, 33%; pregabalin supplemented with amitriptyline, 43%; p = 0.26). No single pathway was superior in cost-effectiveness. The incremental gains in quality-adjusted life-years were small for each pathway comparison [amitriptyline supplemented with pregabalin compared with duloxetine supplemented with pregabalin –0.002 (95% confidence interval –0.011 to 0.007) quality-adjusted life-years, amitriptyline supplemented with pregabalin compared with pregabalin supplemented with amitriptyline –0.006 (95% confidence interval –0.002 to 0.014) quality-adjusted life-years and duloxetine supplemented with pregabalin compared with pregabalin supplemented with amitriptyline 0.007 (95% confidence interval 0.0002 to 0.015) quality-adjusted life-years] and incremental costs over 16 weeks were similar [amitriptyline supplemented with pregabalin compared with duloxetine supplemented with pregabalin −£113 (95% confidence interval −£381 to £90), amitriptyline supplemented with pregabalin compared with pregabalin supplemented with amitriptyline £155 (95% confidence interval −£37 to £625) and duloxetine supplemented with pregabalin compared with pregabalin supplemented with amitriptyline £141 (95% confidence interval −£13 to £398)]. Limitations: Although there was no placebo arm, there is strong evidence for the use of each study medication from randomised placebo-controlled trials. The addition of a placebo arm would have increased the duration of this already long and demanding trial and it was not felt to be ethically justifiable. Future work: Future research should explore (1) variations in diabetic peripheral neuropathic pain management at the practice level, (2) how OPTION-DM (Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus) trial findings can be best implemented, (3) why some patients respond to a particular drug and others do not and (4) what options there are for further treatments for those patients on combination treatment with inadequate pain relief. Conclusions: The three treatment pathways appear to give comparable patient outcomes at similar costs, suggesting that the optimal treatment may depend on patients’ preference in terms of side effects. Trial registration: The trial is registered as ISRCTN17545443 and EudraCT 2016-003146-89. Funding: This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme, and will be published in full in Health Technology Assessment; Vol. 26, No. 39. See the NIHR Journals Library website for further project information.

21 January 2022 in Medicina
Verified
Journal Article
Open access
PDF file
Caroline Ann AbbottCaroline Ann Abbott
Caroline Ann Abbott
KCKatie E. Chatwin
Katie E. Chatwin
SRSatyan M. Rajbhandari
Satyan M. Rajbhandari
KJKanwal M. John
Kanwal M. John
SPSushma Pabbineedi
Sushma Pabbineedi
NRNeil D Reeves
Neil D Reeves
Background and Objectives: Barefoot peak plantar pressures (PPPs) are elevated in diabetes patients with neuropathic foot ulcer (DFU) history; however, there is limited reported evidence for a causative link between high barefoot PPP and DFU risk. We aimed to determine, using a simple mat-based methodology, the site-specific, barefoot PPP critical threshold that will identify a plantar site with a previous DFU. Materials and Methods: In a cross-sectional study, barefoot, site-specific PPPs were measured with normal gait for patients with DFU history (n = 21) and healthy controls (n = 12), using a validated carbon footprint system. For each participant, PPP was recorded at twelve distinct plantar sites (1st–5th toes, 1st–5th metatarsal heads (MTHs), midfoot and heel), per right and left foot, resulting in the analysis of n = 504 distinct plantar sites in the diabetes group, and n = 288 sites in the control group. Receiver operator characteristic curve analysis determined the optimal critical threshold for sites with DFU history. Results: Median PPPs for the groups were: diabetes sites with DFU history (n = 32) = 5.0 (3.25–7.5) kg/cm2, diabetes sites without DFU history (n = 472) = 3.25 (2.0–5.0) kg/cm2, control sites (n = 288) = 2.0 (2.0–3.25) kg/cm2; (p < 0.0001). Diabetes sites with elevated PPP (>6 kg/cm2) were six times more likely to have had DFU than diabetes sites with PPP ≤ 6 kg/cm2 (OR = 6.4 (2.8–14.6, 95% CI), p < 0.0001). PPP > 4.1 kg/cm2 was determined as the optimal critical threshold for identifying DFU at a specific plantar site, with sensitivity/specificity = 100%/79% at midfoot; 80%/65% at 5th metatarsal head; 73%/62% at combined midfoot/metatarsal head areas. Conclusions: We have demonstrated, for the first time, a strong, site-specific relationship between elevated barefoot PPP and previous DFU. We have determined a critical, highly-sensitive, barefoot PPP threshold value of >4.1 kg/cm2, which may be easily used to identify sites of previous DFU occurrence and, therefore, increased risk of re-ulceration. This site-specific approach may have implications for how high PPPs should be investigated in future trials.

13 December 2020 in British Journal of Diabetes
Verified
Journal Article
Closed access
PDF file
SRSatyan M. Rajbhandari
Satyan M. Rajbhandari
KKK Vijay Kumar
K Vijay Kumar
RSRaja Selvarajan
Raja Selvarajan
TMTara Murali
Tara Murali
Background and aims: The burden of diabetes in India is increasing, especially in cities. We conducted a cross- sectional survey of the prevalence of diabetes and a measure of prediabetes in an urban population in Bangalore, India.Methods: Screening was conducted free of charge and without need for a prior appointment in 32 screening sites throughout Bangalore. Diabetes was defined either on the basis of a self-reported prior diagnosis or as undiagnosed diabetes on the basis of a random blood glucose measurement of >11.1 mmol/L (200 mg/dL). A second index of dysglycaemia, termed prediabetes, was defined as a random blood glucose measurement of >7.8 mmol/L (140 mg/dL) but less than 11.1 mmol/L.Results: The study population comprised 3,691 subjects, screened over a period of 15 months. Previously diagnosed diabetes was present in 818 patients (22.2%), previously undiagnosed diabetes in 67 patients (1.8%) and the additional measure of prediabetes in 221 patients (6%). Accordingly, almost one-third of subjects (30%) had diabetes or prediabetes by our criteria. Diabetes (diagnosed or undiagnosed) and prediabetes were more common in older subjects than younger subjects, as would be expected.Conclusions: We observed high rates of dysglycaemia in a large urban population in Bangalore. Our data add to previous reports of a substantial burden of abnormal glucose regulation in this setting. Additional public health initiatives are required to protect the citizens of Bangalore from diabetes and its future complications.

1 March 2003 in Practical Diabetes International
Verified
Journal Article
Open access
PDF file
JBJ Byrne
J Byrne
SGS Garg
S Garg
AVA Vaidya
A Vaidya
SRSatyan M. Rajbhandari
Satyan M. Rajbhandari
SWSc Wallis
Sc Wallis
Thiazolidinediones are a new class of oral hypoglycaemic agents, which have been reviewed by the National Institute for Clinical Excellence (NICE) and guidelines published. There is ambiguity in the NICE guidelines regarding the use of the triple combination of sulphonylurea, metformin and thiazolidinedione to treat type 2 diabetes. However, in our retrospective audit we found that triple therapy was used in 52% of patients treated with thiazolidinediones. When we analysed the effect of triple therapy we found that it significantly (p<0.05) reduced HbA1c from 9.6% (±1.5%) to 8.4% (±1.1%). Further prospective studies will be needed to confirm this. Copyright © 2003 John Wiley & Sons, Ltd. Copyright © 2003 John Wiley & Sons, Ltd.